Cirrhotic patients are at risk for health care-associated bacterial infections

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 11, 2010, Pages

  Merli, Manuela ^a   Lucidi, Cristina ^a   Giannelli, Valerio ^a   Giusto, Michela ^a   Riggio, Oliviero ^a   Falcone, Marco ^a   Ridola, Lorenzo ^a   Attili, Adolfo Francesco ^a   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Multidrug Resistance; Nutritional Status; Sepsis; Survival

Indexed keywords

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; INFECTION RISK; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PREVALENCE; PROTEIN MALNUTRITION; RISK ASSESSMENT; SEPTIC SHOCK; SURVIVAL;

EID: 77958482553     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.06.024     Document Type: Article

References (26)

1. Gustot T., Durand F., Lebrec D., et al. Severe sepsis in cirrhosis. Hepatology 2009, 50:2022-2033.
2. Borzio M., Salerno F., Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001, 33:41-48.
3. Fasolato S., Angeli P., Dallagnese L., et al. Renal failure and bacterial infection in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007, 45:223-229.
4. Wong F., Bernardi M., Balk R., et al. International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005, 54:718-725.
5. Christou L., Pappas G., Falagas M.E. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007, 102:1510-1517.
6. Fernández J., Navasa M., Gómez J., et al. Bacterial Infection in cirrhosis: epidemiological changes with invasive procedures and Norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
7. Fernández J., Ruiz del Arbol L., Gómez C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and haemorrhage. Gastroenterology 2006, 131:1049-1456.
8. Venditti M., Falcone M., Corrao S., et al. Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26.
9. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
10. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
11. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
12. Salerno F., Gerbes A., Ginès P., et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56:1310-1318.
13. Merli M., Riggio O., Dally L. Policentrica Italiana Nutrizione Cirrosi. Does malnutrition affect survival in cirrhosis?. Hepatology 1996, 23:1041-1046.
14. Garcia-Tsao G., Lim J.K. Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension. Am J Gastroenterol 2009, 104:1802-1829.
15. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107.
16. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 43:922-933.
17. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977, 72:573-583.
18. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
19. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55:1619-1629.
20. Rupp M.E., Fey P.D. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63:353-365.
21. Mazzaferro V., Regalio E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
22. Friedman N.D., Kaye K.S., Stout J.E., et al. Health care associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
23. Sam J., Nguyen G.C. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009, 29:1396-1402.
24. Merli M., Giusto M., Gentili F., et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver International 2010, 30:208-214.
25. Trautwein C., Boker K., Manns M.P. Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanism. Gut 1994, 35:1163-1166.
26. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.